Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1993 Jun;92(3):482-6.
doi: 10.1111/j.1365-2249.1993.tb03425.x.

Early IL-2/sIL-2R surge following surgery leads to temporary immune refractoriness

Affiliations

Early IL-2/sIL-2R surge following surgery leads to temporary immune refractoriness

N Lahat et al. Clin Exp Immunol. 1993 Jun.

Abstract

High serum level of immunoreactive but not biologically active IL-2 was detected 1 day after surgery in patients undergoing major operation (abdominal, open-heart), in proportion to the tissue injury caused by surgical trauma. IL-2 values were highest in those patients who underwent open-heart surgery and received blood transfusions. In all patients they declined in the third and fourth post-operative days. Elevated serum levels of soluble IL-2 receptors (sIL-2R) were already present 1 day after operation, and peaked in the third and fifth post-operative days after mitogen triggering. Blood lymphocytes derived from operated patients secreted reduced amounts of both IL-2 and sIL-2R compared with control lymphocytes. The extent and duration of this reduction were also proportional to the tissue trauma and were affected by blood transfusions. Based on these data we suggest that early post-operative systemic immunological activation (appearance of IL-2 in the serum) is followed by elevation of sIL-2R, which then interferes with IL-2-dependent immunity. Blood lymphocytes are probably not involved in the post-operative immunological activation. The trigger for and the site of IL-2/sIL-2R synthesis are not yet clear.

PubMed Disclaimer

References

    1. Lancet. 1971 Jan 9;1(7689):53-5 - PubMed
    1. Clin Exp Immunol. 1992 Nov;90(2):219-22 - PubMed
    1. J Immunol. 1985 Nov;135(5):3172-7 - PubMed
    1. Immunol Lett. 1986 Oct;13(4):179-84 - PubMed
    1. Clin Immunol Immunopathol. 1987 May;43(2):273-6 - PubMed